APA

Robertson J. F. R., Lindemann J. P. O., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Emerson L., Dean A. & Ellis M. J. (20130614). Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. : Breast cancer research and treatment.

Chicago

Robertson John F R, Lindemann Justin P O, Llombart-Cussac Antonio, Rolski Janusz, Feltl David, Dewar John, Emerson Laura, Dean Andrew and Ellis Matthew J. 20130614. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. : Breast cancer research and treatment.

Harvard

Robertson J. F. R., Lindemann J. P. O., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Emerson L., Dean A. and Ellis M. J. (20130614). Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. : Breast cancer research and treatment.

MLA

Robertson John F R, Lindemann Justin P O, Llombart-Cussac Antonio, Rolski Janusz, Feltl David, Dewar John, Emerson Laura, Dean Andrew and Ellis Matthew J. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. : Breast cancer research and treatment. 20130614.